NSPR INSPIREMD INC

InspireMD to Participate in Upcoming November Investor Conferences

InspireMD to Participate in Upcoming November Investor Conferences

TEL AVIV, Israel and MIAMI, Fla., Nov. 02, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for treatment of carotid artery disease and prevention of stroke, today announced that the Marvin Slosman, Chief Executive Officer, will participate in three upcoming investor conferences in November:

Wolfe Research Healthcare Conference

Wednesday, November 15, 2023

Fireside chat: 12:30pm ET

Canaccord Genuity MedTech, Diagnostics, Digital Health & Services Forum

Thursday, November 16, 2023

Investor one-on-one meetings only

Piper 35th Annual Healthcare Conference

Wednesday, November 29, 2023

Fireside chat: 8:00am ET

A live webcast of the presentations will be available in the News and Events section of the Company’s website at /en/events/. Replays will be available on the website for 30 days.

About InspireMD, Inc.

InspireMD seeks to utilize its proprietary MicroNet® technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free, long-term outcomes. InspireMD’s common stock is quoted on the Nasdaq under the ticker symbol NSPR.

We routinely post information that may be important to investors on our website. For more information, please visit .

Investor Contacts:

Craig Shore

Chief Financial Officer

InspireMD, Inc.

888-776-6804

Chuck Padala, Managing Director

LifeSci Advisors

646-627-8390



EN
02/11/2023

Underlying

NSPRINSPIREMD INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on INSPIREMD INC

 PRESS RELEASE
Free
NSPR INSPIREMD INC

InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c...

InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MIAMI, Jan. 20, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced that the Compensation Committee of InspireMD’s Board of Directors approved inducement grants to one (1) new non-executive employee in the aggregate amount of 36,118 shares of restricted stock (the “Inducement Grants”) outside of InspireMD’s 2021 Equity Incentive Plan, with a grant date as of January 14, 2026, as an i...

January 20, 2026 1 EN
 PRESS RELEASE
Free
NSPR INSPIREMD INC

InspireMD Announces Publication of the C-GUARDIANS Pivotal Trial Manus...

InspireMD Announces Publication of the C-GUARDIANS Pivotal Trial Manuscript in the Journal of the American College of Cardiology (JACC) The CGuard® Prime Carotid Stent System demonstrated the lowest 30-day and 1-year primary endpoint major adverse event rates of any pivotal study of carotid stenting (CAS) MIAMI, Jan. 12, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that results from the Company’s C-GUARDIANS pivotal trial have now been published in ...

January 12, 2026 1 EN
 PRESS RELEASE
Free
NSPR INSPIREMD INC

Landmark CREST-2 Study Published in the New England Journal of Medicin...

Landmark CREST-2 Study Published in the New England Journal of Medicine Highlights the Benefits of Carotid Artery Stenting Carotid artery stenting combined with medical therapy demonstrated a significantly lower stroke risk compared to intensive medical therapy alone in patients with severe asymptomatic carotid stenosis MIAMI, Nov. 24, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, welcomes the recent presentation and publication of CREST-2 data which demonstrated p...

November 24, 2025 1 EN
 PRESS RELEASE
Free
NSPR INSPIREMD INC

InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c...

InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MIAMI, Nov. 21, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that the Compensation Committee of InspireMD’s Board of Directors approved inducement grants to eight (8) new non-executive employees in the aggregate amount of 122,054 shares of restricted stock (the “Inducement Grants”) outside of InspireMD’s 2021 Equity Incentive Plan, with a grant date as of November 20, 2025, as...

November 21, 2025 1 EN
 PRESS RELEASE
Free
NSPR INSPIREMD INC

InspireMD to Participate in Upcoming Piper Sandler 37th Annual Healthc...

InspireMD to Participate in Upcoming Piper Sandler 37th Annual Healthcare Conference MIAMI, Nov. 19, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced plans to participate in a fireside discussion at the upcoming Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3rd at 12:30 pm Eastern Time (ET). A live audio webcast and replay of the discussion may be accessed on the “Investor Calendar” section of the company’s website at: About InspireMD, Inc.InspireMD seeks t...

November 19, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch